Skip to main content
Premium Trial:

Request an Annual Quote

Avi Nash, David Harvey, Jai Nagarkatti, Kenneth Horton, David Smith, Vicky Gwosdz, Michael Milburn, Arnold Pinkston, William May, BioImage



Sigma-Aldrich's board of directors elected Avi Nash as a director, the company said last week.

Nash currently heads a management consulting firm, Avi Nash LLC, launched in 2003. Prior to this, he was a partner at Goldman Sachs. He has worked at Booz, Allen & Hamilton and UOP.

Outgoing chief executive officer David Harvey made the announcement.

The board also appointed Jai Nagarkatti, president and chief operating officer of the company since 2004, as president and chief executive officer to replace Harvey, who will remain chairman of the board.

Also elected to the board, Nagarkatti's appointment takes effect on Jan. 1, 2006.

Nagarkatti has been with Sigma-Aldrich for 29 years in R&D, production, operations and sales and marketing. He has a Master's degree in chemistry from Osmania University in Hyderabad, India, and a PhD in organic chemistry from Texas A&M University.

Kenneth Horton has been appointed executive vice-president and general counsel for MDS, the company said last week. He will join MDS at the start of December.

Horton was vice-president and general counsel for the Life and Analytical Sciences business unit of PerkinElmer prior to this appointment. He practiced corporate law with Boston's Ropes and Gray and as a strategy consultant in the U.S. and Europe.

He has a JD from Harvard Law School and an AB from Dartmouth College.

David Smith has joined Galapagos as chief financial officer, the Belgium-based company said today.

The appointment takes effect Feb. 1, 2006.

Smith joins Galapagos after eight years with AstraZeneca Netherlands. Vicky Gwosdz, currently head of finance of Galapagos, will continue as controller.

Smith also trained as a chartered accountant with Coopers & Lybrand, Leeds. He has a degree in molecular biophysics from the University of Leeds.

Michael Milburn has joined Metabolon as its chief scientific officer, the company said last week.

Prior to Metabolon, Milburn was senior vice-president of research and corporate development at Sirtris Pharmaceuticals. He was also senior vice-president of research at Plexxikon and held positions at Structural Genomix and GlaxoSmithKline.

He received his PhD in structural chemistry at the University of California, Berkeley, and was a research fellow at Harvard Medical School.

Beckman Coulter has named Arnold Pinkston as senior vice president, general counsel, and secretary, the company said earlier this week.

The vice-president and counsel appointments are effective Nov. 15, 2005. The secretary appointment is effective Dec. 1, pending board approval. Pinkston will succeed William May, who is retiring.

Most recently, Pinkston was deputy general counsel for Lilly USA, part of the Eli Lilly Corporation. He currently serves on the board of directors of St. Vincent Health and Southwest Autism Research Center.



BioImage last week launched two new assays that use the company's Redistribution technology: a ß-Catenin Redistribution assay and a Rad51 Redistribution assay.

According to BioImage, the ß-catenin Redistribution assay is designed to assay for antagonists of ß-catenin translocation by monitoring the translocation of a GFP-ß-catenin fusion protein from the membrane to the nucleus. The Rad51 assay is designed to assay for compounds inducing replication-associated DNA double-stranded breaks, as such compounds lead to accumulation of the Rad51-GFP fusion protein in foci within the nucleus.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.